The Enzyme Nobody Watched: How Mitapivat’s Phase 3 Win Rewrites the Rules for Sickle Cell Drug Development

Mitapivat achieved a 40.6% hemoglobin response rate in the RISE UP Phase 3 trial, with its endpoint strategy potentially influencing future approaches in rare disease drug development.

Read the original report from The Clinical Trial Vanguard.